Shillong Herald

Atopic Dermatitis Pipeline & Clinical Trials Report | 100+ Companies and 100+ Drugs

 Breaking News
  • No posts were found

Atopic Dermatitis Pipeline & Clinical Trials Report | 100+ Companies and 100+ Drugs

January 12
20:08 2023
Atopic Dermatitis Pipeline & Clinical Trials Report | 100+ Companies and 100+ Drugs

DelveInsight’s, “Atopic Dermatitis Pipeline Insight, 2023” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Atopic Dermatitis pipeline landscape. It covers the Atopic Dermatitis pipeline drug profiles, including Atopic Dermatitis clinical trial and nonclinical stage products. It also covers the Atopic Dermatitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Atopic Dermatitis Pipeline Report

  • DelveInsight’s Atopic Dermatitis pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for atopic dermatitis treatment.
  • The leading Atopic Dermatitis Companies include Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc, Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others. Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc,, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, Vanda Pharmaceuticals, Kyowa Kirin, Sanofi, KeyMed Biosciences, Asana BioSciences, Bristol-Myers Squibb, RAPT Therapeutics, Allakos, Novartis, BioMimetix, Shanghai Hengrui Pharmaceutical Co, Connect Biopharma, Pfizer, Evommune, Inc., Fresh Tracks Therapeutics, Biosion, Chia Tai Tianqing Pharmaceutical, Reistone Biopharma Company Limited, JW Pharmaceutical, Oneness Biotech, Alphyn Biologics, selectION, UNION Therapeutics, Ichnos Sciences, and others
  • Promising Atopic Dermatitis pipeline therapies include BX 005, LP 0145, AR 100, SCM AGH, SCD-044, BBI 02, UCB9741, ARQ-151, Amlitelimab, LP 0145, GSK 1070806, AR 100, SCM AGH, SCD-044, BBI 02, Lebrikizumab, Tozorakimab, UCB9741, ARQ-151, Rocatinlimab, SAR444656, Amlitelimab, Rilzabrutinib, Atuzabrutinib, LP0145, CM 310, ARQ-234, ASN002, ASN008, BMS-986166, RPT 193, BMS-986265, AK002, EDP1815, CEE321, CMK 389, BMX-010, SHR1819, CBP-201, PF-07038124, Cendakimab, EVO101, PF-07275315, BSI 045B, RBN-3143, TQH2722, SHR0302, JWP 1601, FB825, AB-101a, si-544, Orismilast, ISB 830, and others.
  • The Atopic Dermatitis Companies and academics are working to assess challenges and seek opportunities that could influence Atopic Dermatitis R&D. The Atopic Dermatitis pipeline therapies under development are focused on novel approaches to treat/improve Diffuse Large B-Cell Lymphoma.

 

Explore more about the latest breakthroughs of Atopic Dermatitis Treatment Landscape report @ Atopic Dermatitis Pipeline Outlook

 

Atopic Dermatitis Overview

Atopic dermatitis, often referred to as eczema, is a chronic (long-lasting) disease that causes inflammation, redness, and irritation of the skin. It is a common condition that usually begins in childhood; however, anyone can get the disease. Atopic dermatitis is not contagious, so it cannot be spread from person to person. Atopic dermatitis causes the skin to become extremely itchy. Scratching leads to further redness, swelling, cracking, “weeping” clear fluid, crusting, and scaling. In most cases, there are periods of time when the disease is worse, called flares, followed by periods when the skin improves or clears up entirely, called remissions. Researchers do not know what causes atopic dermatitis, but they do know that genes, the immune system, and the environment play a role in the disease. Depending on the severity and location of the symptoms, living with atopic dermatitis can be hard. Treatment can help control symptoms.

 

Recent Developmental Activities in the Atopic Dermatitis Treatment Landscape

  • In November 2022, Alphyn Biologics announced that it had completed the first cohort of its Phase IIa clinical trial of AB-101a, a topical therapeutic candidate for mild-to-moderate atopic dermatitis (AD) in adults and children as young as 2 years old. The first cohort enrolled AD patients without bacterial infection, which is sometimes associated with the disease. Top-line results are expected in approximately eight weeks.
  • In September 2022, selectION announced that it has begun dosing patients in a Phase Ib trial to evaluate safety and efficacy, including duration of clinical benefit, of si-544 in patients with mild to severe atopic dermatitis.
  • In July 2022, Connect Biopharma Holdings announced it has been informed by the Center for Drug Evaluation of the National Medical Products Administration (CDE), that it can conduct primary analysis of its ongoing pivotal trial for its lead product candidate CBP-201 to treat adult patients with moderate-to-severe atopic dermatitis (AD) based on the 255 patients. As a result, Connect Biopharma plans to report this trial’s top-line results by year-end, earlier than originally planned.
  • In May 2022, Brickell Biotech announced that the first subjects were dosed in the single ascending dose of Phase I clinical trial evaluating BBI-02 in healthy adult subjects and patients with atopic dermatitis. BBI-02 is a potential first-in-class, highly selective, orally bioavailable small molecule DYRK1A inhibitor that aims to restore immune balance through modulating adaptive and innate immune responses in patients with autoimmune and inflammatory diseases
  • In November 2021, The Food and Drug Administration (FDA) granted Fast Track designation to orismilast for the treatment of moderate to severe atopic dermatitis. Orismilast is a selective next generation phosphodiesterase-4 (PDE4) inhibitor with broad anti-inflammatory properties.

 

Learn more about the Atopic Dermatitis Emerging Therapies @ Atopic Dermatitis Ongoing Clinical Trials Analysis

 

Atopic Dermatitis Emerging Drugs Profile

 

Amlitelimab: Kymab

Amlitelimab SAR445229 (formerly KY1005) is a human monoclonal antibody that targets OX40L, a key regulator of the immune system. Amlitelimab is designed to rebalance the immune system by blocking inappropriate activation and proliferation of ‘pro-inflammatory’ effector T cells and promoting expansion of ‘anti-inflammatory’ regulatory T cells, without broad suppression of the immune system. It is believed this mechanism-of-action means Amlitelimab could be applicable to a range of autoimmune and inflammatory diseases. In Phase I clinical trial in healthy volunteers, Amlitelimab was able to block T cell-driven skin inflammation while being well tolerated. It is believed the immune-modulating mechanism of Amlitelimab has broad potential therapeutic application in multiple diseases caused by immune dysregulation. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.

 

BX 005: BiomX

BX005, a topical phage cocktail that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In preclinical in vitro studies, BX005 was shown to be active against over 90% of strains of S. aureus isolated from the skin of subjects from U.S. and Europe, including antibiotic resistant strains. Currently, the drug is being developed in the Phase I/II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.

 

LP 0145: LEO Pharma

LP 0145, is an anti-inflammatory monoclonal antibody under development for atopic dermatitis. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.

 

Atopic Dermatitis Therapeutics Assessment

There are approx. 100+ key companies which are developing the therapies for Atopic Dermatitis. The companies which have their Atopic Dermatitis drug candidates in the most advanced stage, i.e. Phase II include, LEO Pharma.

 

Dive deep into rich insights for new drugs for Atopic Dermatitis Medications and Therapies; visit @ Atopic Dermatitis Treatment Landscape

 

Scope of the Atopic Dermatitis Pipeline Report

 

  • Coverage- Global
  • Companies- Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc, Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others. Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc,, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, Vanda Pharmaceuticals, Kyowa Kirin, Sanofi, KeyMed Biosciences, Asana BioSciences, Bristol-Myers Squibb, RAPT Therapeutics, Allakos, Novartis, BioMimetix, Shanghai Hengrui Pharmaceutical Co, Connect Biopharma, Pfizer, Evommune, Inc., Fresh Tracks Therapeutics, Biosion, Chia Tai Tianqing Pharmaceutical, Reistone Biopharma Company Limited, JW Pharmaceutical, Oneness Biotech, Alphyn Biologics, selectION, UNION Therapeutics, Ichnos Sciences, and others.
  • Atopic Dermatitis Pipeline Therapies: BX 005, LP 0145, AR 100, SCM AGH, SCD-044, BBI 02, UCB9741, ARQ-151, Amlitelimab, LP 0145, GSK 1070806, AR 100, SCM AGH, SCD-044, BBI 02, Lebrikizumab, Tozorakimab, UCB9741, ARQ-151, Rocatinlimab, SAR444656, Amlitelimab, Rilzabrutinib, Atuzabrutinib, LP0145, CM 310, ARQ-234, ASN002, ASN008, BMS-986166, RPT 193, BMS-986265, AK002, EDP1815, CEE321, CMK 389, BMX-010, SHR1819, CBP-201, PF-07038124, Cendakimab, EVO101, PF-07275315, BSI 045B, RBN-3143, TQH2722, SHR0302, JWP 1601, FB825, AB-101a, si-544, Orismilast, ISB 830, and others.
  • Atopic Dermatitis Segmentation: Phases, Molecule Type, Mechanism of Action, Route of Administration, Product Type

 

 

Table of Content

  1. Introduction
  2. Atopic Dermatitis Executive Summary
  3. Atopic Dermatitis: Overview
  4. Atopic Dermatitis Pipeline Therapeutics
  5. Atopic Dermatitis Therapeutic Assessment
  6. Atopic Dermatitis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name : Company name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Amlitelimab: Kymab
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. Drug name : Company name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name : Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Atopic Dermatitis Key Companies
  21. Atopic Dermatitis Key Products
  22. Atopic Dermatitis- Unmet Needs
  23. Atopic Dermatitis- Market Drivers and Barriers
  24. Atopic Dermatitis- Future Perspectives and Conclusion
  25. Atopic Dermatitis Analyst Views
  26. Atopic Dermatitis Key Companies
  27. Appendix

 

For further information on the Atopic Dermatitis Pipeline Therapeutics, reach out @ Atopic Dermatitis Market Drivers and Barriers

 

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles